Venus Concept (VERO) Scheduled to Post Earnings on Monday

Venus Concept (NASDAQ:VERO) will be releasing its earnings data before the market opens on Monday, April 1st. Persons that wish to register for the company’s earnings conference call can do so using this link.

Venus Concept Stock Down 4.0 %

Venus Concept stock opened at $0.69 on Friday. The stock has a 50-day simple moving average of $1.02 and a 200 day simple moving average of $1.45. Venus Concept has a 12-month low of $0.60 and a 12-month high of $4.70. The stock has a market capitalization of $3.82 million, a price-to-earnings ratio of -0.10 and a beta of 0.66.

Institutional Trading of Venus Concept

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. HighTower Advisors LLC bought a new stake in Venus Concept during the 1st quarter worth about $31,000. Vanguard Group Inc. grew its position in shares of Venus Concept by 2.3% during the 1st quarter. Vanguard Group Inc. now owns 1,121,558 shares of the company’s stock worth $1,603,000 after buying an additional 25,630 shares during the period. Bank of New York Mellon Corp grew its position in shares of Venus Concept by 140.2% during the 1st quarter. Bank of New York Mellon Corp now owns 86,578 shares of the company’s stock worth $124,000 after buying an additional 50,530 shares during the period. Prelude Capital Management LLC grew its position in shares of Venus Concept by 73.4% during the 1st quarter. Prelude Capital Management LLC now owns 177,246 shares of the company’s stock worth $253,000 after buying an additional 75,000 shares during the period. Finally, SVB Financial Group acquired a new position in shares of Venus Concept during the 4th quarter worth about $51,000. 87.41% of the stock is owned by institutional investors.

Venus Concept Company Profile

Venus Concept Inc, a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes aesthetic device platforms, including Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin.